8 results match your criteria: "National Institute of Neoplastic Diseases INEN[Affiliation]"
Ecancermedicalscience
September 2023
Pathology Department, National Institute of Neoplastic Diseases (INEN), Lima 15038, Peru.
45,X/46,XY mosaicism is a sex development disorder with an estimated incidence of less than 1 in 15,000 live births. Various studies have shown there is an increased risk of germ cell tumours forming in Mosaic Turner syndrome. This includes gonadoblastoma, a clinically benign mixed germ-stromal cell tumour.
View Article and Find Full Text PDFHeliyon
May 2023
Department of Abdominal Surgery, National Institute of Neoplastic Diseases INEN, Lima, Peru.
Purpose: This study aimed to identify the predictive factors of lymph node metastasis (LNM) in patients with early gastric cancer (EGC) and to evaluate the applicability of the Japanese treatment guidelines for endoscopic resection in the western population.
Methods: Five hundred-one patients with pathological diagnoses of EGC were included. Univariate and multivariate analyses were conducted to identify the predictive factors of LNM.
Discov Oncol
November 2021
Department of Abdominal Surgery, National Institute of Neoplastic Diseases INEN, Lima, Peru.
Purpose: Solid pseudopapillary neoplasm (SPN) is an uncommon pathology with a low-grade malignancy. Surgery is the milestone treatment. Nevertheless, despite appropriate management, some patients present recurrence.
View Article and Find Full Text PDFHeliyon
June 2021
Department of Abdominal Surgery, National Institute of Neoplastic Diseases INEN, Lima Peru.
Purpose: The role of tumor deposits (TDs) in the staging of gastric cancer is currently debatable. TDs are defined as tumoral nodules in perigastric adipose tissue with no evidence of lymphatic, vascular, or neural structures. Clinicopathological factors related to the presence of TDs are not well defined.
View Article and Find Full Text PDFPediatr Surg Int
August 2021
Department of Abdominal Surgery, National Institute of Neoplastic Diseases INEN, Holbein Street 107, Lima, Perú.
Purpose: Pancreas tumors are extremely rare in pediatric and adolescent patients. Surgical resection is the mainstay of treatment; however, the data are limited with respect to morbidity and mortality. We aimed to evaluate short- and long-term outcomes of pediatric and adolescent patients who underwent surgical resection of pancreatic tumors.
View Article and Find Full Text PDFWe present the case of a 27-year old female with an ovarian tumor and alpha-fetoprotein (AFP) of 1210 ng/m, a right salpingo-oophorectomy was performed and had conservative complementary staging by gynecologic oncologists. The histopathological report was primary hepatoid carcinoma of the ovary (HCO), clinical stage IA, complementary treatment was adjuvant chemotherapy with BEP and remains clinical, imaging and biochemically disease free in three years follow up.
View Article and Find Full Text PDFEcancermedicalscience
May 2018
Ophthalmic Oncology Department, National Institute of Neoplastic Diseases (INEN), Lima 15038, Peru.
Introduction: In ocular conjunctival carcinoma after surgery, adjuvant treatment has a role and kilovoltage surface brachytherapy opens a new door for the range of therapeutic options.
Materials And Methods: Between October 2014 and June 2017, at the National Institute of Neoplastic Diseases (INEN) from Peru, 39 patients with squamous cell carcinoma of ocular conjunctiva, T1-T3, resected, were selected to receive adjuvant treatment. The portable accelerator of 50-kV INTRABEAM (Carl Zeiss Meditec) was used, after local anaesthesia and blocking of ocular muscles movement.
Anticancer Drugs
March 2012
National Institute of Neoplastic Diseases (INEN), Lima, Peru.
The objective of the study was to evaluate the safety, pharmacokinetics, and antitumor activity of ispinesib, a kinesin spindle protein inhibitor. Patients with locally advanced or metastatic breast cancer who had received only prior neoadjuvant or adjuvant chemotherapy were treated with escalating doses of ispinesib administered as a 1-h infusion on days 1 and 15 every 28 days until toxicity or progression of disease. Doses were escalated until dose-limiting toxicity was observed in two out of six patients during cycle 1.
View Article and Find Full Text PDF